Ennature Biopharma Launches Life-Stage Botanicals for Women's Health Market
Ennature Biopharma introduces three new botanical ingredients – Gingeren, Aspargize, and Maxicuma – targeting women's health across adolescence, menopause, and post-menopause. These offerings leverage standardised extracts and advanced delivery systems, positioning them for high-efficacy formulation in the UK's growing women's health sector.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 22 May 2024
Ennature Biopharma has unveiled a new suite of botanical ingredients designed to address specific women's health needs across various life stages, from adolescence through post-menopause. This launch aligns with the nutraceutical industry's pivot towards personalised, evidence-backed solutions, moving beyond general wellness to target distinct physiological challenges.
The current women's health supplement market exhibits growth, yet significant gaps persist, particularly in perimenopausal and postmenopausal care, where symptoms are often normalised. Issues such as dysmenorrhea, hormonal imbalances, and mobility concerns remain under-addressed by one-size-fits-all products. Ennature Biopharma's strategy focuses on delivering high-quality, clinically-validated botanical solutions that offer consistent efficacy through standardised extracts and innovative delivery formats. This approach aims to bridge nutritional deficiencies and support hormonal balance, thereby enhancing overall quality of life for female consumers.
Three key ingredients anchor this new portfolio: Gingeren, Aspargize, and Maxicuma. Gingeren, derived from ginger and standardised to 20% total gingerols, employs a patented sustained-release system. This technology extends the half-life of active compounds by up to five times, overcoming traditional ginger extract limitations of rapid metabolism and poor tolerability. A clinical trial, due for completion by December 2025, investigates 200 mg/day supplementation for menstrual cramp relief, mood balance, and broader immune support. Aspargize, a full-spectrum shatavari root extract standardised to over 5% total shatavarins, targets menopausal symptoms like hot flashes, fatigue, and mood fluctuations. Enhanced with a natural bio-enhancing complex, it is undergoing a clinical study, expected to conclude by September 2025, at a 400 mg/day dose. Lastly, Maxicuma leverages Ennature’s proprietary Lecithin-based Liposomal Microencapsulation (LIMAN™) technology to deliver 172 times more free curcumin in human plasma compared to conventional extracts. Standardised to 40% curcuminoids, Maxicuma supports joint comfort and mobility at ultra-low doses of 100–250 mg/day, with a clinical study currently under peer review.
What this means for United Kingdom
UK supplement manufacturers and brand owners can leverage these advanced botanicals to develop differentiated products within a rapidly expanding women's health category. The clinical validation and enhanced bioavailability of Gingeren, Aspargize, and Maxicuma reduce formulation risk and support premium positioning, offering clear marketing claims for conditions like dysmenorrhea and menopausal symptoms. The low efficacious doses translate to cost efficiencies in raw material sourcing and increased formulation flexibility for diverse delivery formats. Regulatory teams must ensure compliance with UK Novel Food regulations if these ingredients are new to the market or present in novel forms, and prepare for potential MHRA scrutiny on specific health claims, especially regarding hormonal support and pain relief. Brands can gain a competitive edge by targeting specific life stages where consumer demand outstrips current effective offerings, particularly in the perimenopausal and adolescent menstrual health sectors.
The focus on improved bioavailability and sustained release addresses key consumer pain points regarding supplement efficacy and tolerability. Ennature Biopharma is promoting these ingredients at industry events such as Vitafoods Asia 2025, signalling their readiness for broader market adoption and partnership opportunities.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.